Details of Drug

Drug General Information (ID: D0409)
Drug Name	Dacomitinib
Drug Type	Small molecule
Drug Synonymous	PF-00299804 Click to Show/Hide
Disease Class	2C25: Lung cancer
Therapeutic Class	Antineoplastics/Her2 Inhibitors
Structure
Structure	3D Structure		2D Structure
Formula	C24H25ClFN5O2
InChI	1S/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29)/b6-5+
InChIKey	LVXJQMNHJWSHET-AATRIKPKSA-N
Canonical SMILES	COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)C=CCN4CCCCC4
External Link
	Pubchem ID	11511120
	CAS Number	1110813-31-4
	CHEBI ID	91466
	TTD ID	D06XXH
	INTEDE ID	DR0407
	VARIDT ID	DR00109

Drug-Drug Interaction Network
Sunburst Graph		Legend Information AM001 Affected gastrointestinal absorption AM002 Affected cellular transport AM004 Affected intra/extra-hepatic metabolism AM006 Pharmacodynamic additive effects BM005 Altered gastric pH BM010 Transporter inhibition BM017 CYP450 enzyme inhibition BM019 UGT inhibition BM038 Additive CNS depression effects BM109 Increased risk of other adverse reactions (Unspecific)
Relation Graph

Full list of drugs interacting with Dacomitinib
Affected gastrointestinal absorption
	Altered gastric pH					Drug Num: 11
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0458		Dexlansoprazole	C16H14F3N3O2S	9578005	Major		Inter Info	[12], [13]
D0603		Esomeprazole	C17H19N3O3S	9568614	Major		Inter Info	[12], [13]
D0892		Lansoprazole	C16H14F3N3O2S	3883	Major		Inter Info	[12], [13]
D1179		Omeprazole	C17H19N3O3S	4594	Major		Inter Info	[12], [13]
D1222		Pantoprazole	C16H15F2N3O4S	4679	Major		Inter Info	[12], [13]
D1373		Rabeprazole	C18H21N3O3S	5029	Major		Inter Info	[12], [13]
D0337		Cimetidine	C10H16N6S	2756	Moderate		Inter Info	[12], [13]
D0636		Famotidine	C8H15N7O2S3	5702160	Moderate		Inter Info	[12], [13]
D1151		Nizatidine	C12H21N5O2S2	3033637	Moderate		Inter Info	[12], [13]
D1381		Ranitidine	C13H22N4O3S	3001055	Moderate		Inter Info	[12], [13]
D1382		Ranitidine (bismuth citrate)	C13H22N4O3S	3001055	Moderate		Inter Info	[12], [13]
Affected cellular transport
	Transporter inhibition					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0182		Binimetinib	C17H15BrF2N4O3	10288191	Moderate		Inter Info	[18], [12], [76]
Affected intra/extra-hepatic metabolism
	CYP450 enzyme inhibition					Drug Num: 75
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0119		Atomoxetine	C17H21NO	54841	Major		Inter Info	[1], [2], [3]
D0202		Brexpiprazole	C25H27N3O2S	11978813	Major		Inter Info	[4]
D0452		Deutetrabenazine	C19H27NO3	73437646	Major		Inter Info	[5]
D1169		Oliceridine	C22H30N2O2S	66553195	Major		Inter Info	[6], [7]
D1258		Pexidartinib	C20H15ClF3N5	25151352	Major		Inter Info	[8], [9]
D0559		Eliglustat	C23H36N2O4	23652731	Major		Inter Info	[14], [15]
D0791		Iloperidone	C24H27FN2O4	71360	Major		Inter Info	[16]
D1292		Pimozide	C28H29F2N3O	16362	Major		Inter Info	[17], [18], [12], [19], [20], [2]
D1302		Pitolisant	C17H26ClNO	9948102	Major		Inter Info	[12], [21]
D1533		Tamoxifen	C26H29NO	2733526	Major		Inter Info	[22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47], [15], [48], [49], [50], [51], [52], [53], [54], [55]
D1560		Tetrabenazine	C19H27NO3	6018	Major		Inter Info	[56]
D1574		Thioridazine	C21H26N2S2	5452	Major		Inter Info	[57], [58], [59]
D1708		Vortioxetine	C18H22N2S	9966051	Major		Inter Info	[61]
D0068		Amitriptyline	C20H23N	2160	Moderate		Inter Info	[13]
D0072		Amoxapine	C17H16ClN3O	2170	Moderate		Inter Info	[13]
D0074		Amphetamine	C9H13N	3007	Moderate		Inter Info	[13]
D0105		Aripiprazole	C23H27Cl2N3O2	60795	Moderate		Inter Info	[62]
D0112		Asenapine	C17H16ClNO	3036780	Moderate		Inter Info	[13]
D0267		Carvedilol	C24H26N2O4	2585	Moderate		Inter Info	[13]
D0308		Cevimeline	C10H17NOS	83898	Moderate		Inter Info	[63]
D0323		Chlorpheniramine	C16H19ClN2	2725	Moderate		Inter Info	[13]
D0324		Chlorpromazine	C17H19ClN2S	2726	Moderate		Inter Info	[13]
D0361		Clomipramine	C19H23ClN2	2801	Moderate		Inter Info	[13]
D0370		Clozapine	C18H19ClN4	135398737	Moderate		Inter Info	[13]
D0379		Codeine	C18H21NO3	5284371	Moderate		Inter Info	[64], [65], [66], [67], [68], [69], [15], [70], [71], [72], [73], [74], [75]
D0424		Darifenacin	C28H30N2O2	444031	Moderate		Inter Info	[77], [78]
D0446		Desipramine	C18H22N2	2995	Moderate		Inter Info	[13]
D0457		Dexfenfluramine	C12H16F3N	66265	Moderate		Inter Info	[13]
D0466		Dextromethorphan	C18H25NO	5360696	Moderate		Inter Info	[18], [12], [79], [80], [78], [81]
D0467		Dextropropoxyphene	C22H29NO2	10100	Moderate		Inter Info	[13]
D0502		Diphenhydramine	C17H21NO	3100	Moderate		Inter Info	[13]
D0525		Doxepin	C19H21NO	667477	Moderate		Inter Info	[13]
D0526		Doxepin (topical)	C19H21NO	667477	Moderate		Inter Info	[13]
D0528		Doxorubicin	C27H29NO11	31703	Moderate		Inter Info	[13]
D0529		Doxorubicin (liposomal)	C27H29NO11	31703	Moderate		Inter Info	[13]
D0539		Duloxetine	C18H19NOS	60835	Moderate		Inter Info	[82], [83]
D0641		Fenfluramine	C12H16F3N	3337	Moderate		Inter Info	[13]
D0664		Flecainide	C17H20F6N2O3	3356	Moderate		Inter Info	[13]
D0676		Fluoxetine	C17H18F3NO	3386	Moderate		Inter Info	[13]
D0678		Fluphenazine	C22H26F3N3OS	3372	Moderate		Inter Info	[13]
D0687		Fluvoxamine	C15H21F3N2O2	5324346	Moderate		Inter Info	[13]
D0707		Galantamine	C17H21NO3	9651	Moderate		Inter Info	[13]
D0713		Gefitinib	C22H24ClFN4O3	123631	Moderate		Inter Info	[13]
D0750		Haloperidol	C21H23ClFNO2	3559	Moderate		Inter Info	[13]
D0795		Imipramine	C19H24N2	3696	Moderate		Inter Info	[13]
D0979		Maprotiline	C20H23N	4011	Moderate		Inter Info	[13]
D0987		Meclizine	C25H27ClN2	4034	Moderate		Inter Info	[13]
D1010		Mesoridazine	C21H26N2OS2	4078	Moderate		Inter Info	[13]
D1012		Metamfetamine	C10H15N	10836	Moderate		Inter Info	[13]
D1026		Methotrimeprazine	C19H24N2OS	72287	Moderate		Inter Info	[13]
D1046		Metoclopramide	C14H22ClN3O2	4168	Moderate		Inter Info	[13]
D1049		Metoprolol	C15H25NO3	4171	Moderate		Inter Info	[13]
D1054		Mexiletine	C11H17NO	4178	Moderate		Inter Info	[13]
D1061		Midodrine	C12H18N2O4	4195	Moderate		Inter Info	[13]
D1075		Mirtazapine	C17H19N3	4205	Moderate		Inter Info	[86], [87], [15], [88], [89]
D1114		Nebivolol	C22H25F2NO4	71301	Moderate		Inter Info	[13]
D1158		Nortriptyline	C19H21N	4543	Moderate		Inter Info	[13]
D1229		Paroxetine	C19H20FNO3	43815	Moderate		Inter Info	[13]
D1257		Perphenazine	C21H26ClN3OS	4748	Moderate		Inter Info	[13]
D1299		Pirfenidone	C12H11NO	40632	Moderate		Inter Info	[12], [90], [15]
D1352		Promethazine	C17H20N2S	4927	Moderate		Inter Info	[13]
D1353		Propafenone	C21H27NO3	4932	Moderate		Inter Info	[13]
D1357		Propranolol	C16H21NO2	4946	Moderate		Inter Info	[13]
D1361		Protriptyline	C19H21N	4976	Moderate		Inter Info	[13]
D1413		Risperidone	C23H27FN4O2	5073	Moderate		Inter Info	[13]
D1415		Ritonavir	C37H48N6O5S2	392622	Moderate		Inter Info	[13]
D1534		Tamsulosin	C20H28N2O5S	129211	Moderate		Inter Info	[91], [92], [93], [15]
D1585		Timolol	C13H24N4O3S	33624	Moderate		Inter Info	[13]
D1586		Timolol (ophthalmic)	C13H24N4O3S	33624	Moderate		Inter Info	[94], [95], [96]
D1616		Tramadol	C16H25NO2	33741	Moderate		Inter Info	[13]
D1624		Trazodone	C19H22ClN5O	5533	Moderate		Inter Info	[13]
D1647		Trimipramine	C20H26N2	5584	Moderate		Inter Info	[13]
D0516		Donepezil	C24H29NO3	3152	Minor		Inter Info	[97], [15], [98], [99]
D1383		Ranolazine	C24H33N3O4	56959	Minor		Inter Info	[100]
D1607		Tolterodine	C22H31NO	443879	Minor		Inter Info	[101], [102], [15]
	UGT inhibition					Drug Num: 2
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1435		Sacituzumab govitecan	C76H104N12O24S	91668186	Major		Inter Info	[10], [11]
D0959		Lumateperone	C24H28FN3O	21302490	Moderate		Inter Info	[85]
Pharmacodynamic additive effects
	Additive CNS depression effects					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1673		Valbenazine	C24H38N2O4	24795069	Major		Inter Info	[60]
	Increased risk of other adverse reactions (Unspecific)					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0789		Idelalisib	C22H18FN7O	11625818	Moderate		Inter Info	[84]

References
1	Belle DJ, Ernest CS, Sauer JM, Smith BP, Thomasson HR, Witcher JW "Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics." J Clin Pharmacol 42 (2002): 1219-27. [PMID: 12412820]
2	Product Information. Paxil (paroxetine). GlaxoSmithKline, Research Triangle Park, NC.
3	Product Information. Strattera (atomoxetine). Lilly, Eli and Company, Indianapolis, IN.
4	Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
5	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
6	Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41. [PMID: 10721388]
7	Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
8	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
9	Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67. [PMID: 19667002]
10	Product Information. Nexavar (sorafenib). Bayer Pharmaceutical Inc, West Haven, CT.
11	Product Information. Trodelvy (sacituzumab govitecan). Immunomedics, Morris Plains, NJ.
12	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
13	Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
14	Product Information. Cerdelga (eliglustat). Genzyme Corporation, Cambridge, MA.
15	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
16	Product Information. Fanapt (iloperidone). Vanda Pharmaceuticals Inc, Rockville, MD.
17	Canadian Pharmacists Association.
18	Cerner Multum, Inc. "Australian Product Information.".
19	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
20	Product Information. Orap Tablets (pimozide). Gate Pharmaceuticals, Sellersville, PA.
21	Product Information. Wakix (pitolisant). Harmony Biosciences, LLC, Plymouth Meeting, PA.
22	Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51. [PMID: 11304901]
23	Aubert RE, Stanek EJ, Yao J, et al "Increased risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors".
24	Bonanni B, Macis D, Maisonneuve P, et al. "Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial." J Clin Oncol 24 (2006): 3708-9. [PMID: 16877740]
25	Borges S, Desta Z, Li L, et al. "Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment." Clin Pharmacol Ther 80 (2006): 61-74. [PMID: 16815318]
26	Borgna JL, Rochefort H "Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues." J Biol Chem 256 (1981): 859-68. [PMID: 7451477]
27	Brauch H, Murdter TE, Eichelbaum M, Schwab M "Pharmacogenomics of tamoxifen therapy." Clin Chem 55 (2009): 1770-82. [PMID: 19574470]
28	Coller JK, Krebsfaenger N, Klein K, et al. "The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver." Br J Clin Pharmacol 54 (2002): 157-167. [PMID: 12207635]
29	Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE "The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes." Br J Clin Pharmacol 34 (1992): 262-5. [PMID: 1389951]
30	Dehal SS, Kupfer D "CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver." Cancer Res 57 (1997): 3402-6. [PMID: 9270005]
31	Desta Z, Flockhart DA "Germline pharmacogenetics of tamoxifen response: have we learned enough?" J Clin Oncol 25 (2007): 5147-9. [PMID: 18024859]
32	Desta Z, Ward BA, Soukhova NV, Flockhart DA "Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6." J Pharmacol Exp Ther (2004):. [PMID: 15159443]
33	Dezentje VO, Guchelaar HJ, Nortier JW, van de Velde CJ, Gelderblom H "Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer." Clin Cancer Res 15 (2009): 15-21. [PMID: 19118028]
34	Gaston C, Kolesar J "Clinical Significance of CYP2D6 Polymorphisms and Tamoxifen in Women with Breast Cancer." Clin Adv Hematol Oncol 6 (2008): 825-33. [PMID: 19194367]
35	Goetz MP, Kamal A, Ames MM "Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response." Clin Pharmacol Ther (2007):. [PMID: 17882159]
36	Goetz MP, Loprinzi CL "A hot flash on tamoxifen metabolism." J Natl Cancer Inst 95 (2003): 1734-5. [PMID: 14652227]
37	Goetz MP, Rae JM, Suman VJ, et al. "Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes." J Clin Oncol 23 (2005): 9312-8. [PMID: 16361630]
38	Henry NL, Stearns V, Flockhart DA, Hayes DF, Riba M "Drug interactions and pharmacogenomics in the treatment of breast cancer and depression." Am J Psychiatry 165 (2008): 1251-5. [PMID: 18829880]
39	Jin Y, Desta Z, Stearns V, et al. "CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment." J Natl Cancer Inst 97 (2005): 30-9. [PMID: 15632378]
40	Johnson MD, Zuo H, Lee KH, et al. "Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen." Breast Cancer Res Treat 85 (2004): 151-9. [PMID: 15111773]
41	Jordan VC "Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance." Breast Cancer Res Treat 2 (1982): 123-38. [PMID: 6184101]
42	Jordan VC, Collins MM, Rowsby L, Prestwich G "A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity." J Endocrinol 75 (1977): 305-16. [PMID: 591813]
43	Lash TL, Pedersen L, Cronin-Fenton D, et al "Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram." Br J Cancer 99 (2008): 616-21. [PMID: 20385012]
44	Lehmann D, Nelsen J, Ramanath V, Newman N, Duggan D, Smith A "Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition." J Clin Pharmacol 44 (2004): 861-5. [PMID: 15286089]
45	Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J "Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer." J Clin Oncol 25 (2007): 3837-45. [PMID: 17761971]
46	McCaffrey P "Genetics and drug interactions affect tamoxifen metabolism." Lancet Oncol 6 (2005): 72. [PMID: 15704296]
47	Ponzone R, Biglia N, Sismondi P "Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 96 (2004): 883-4 author reply 884-5. [PMID: 15173274]
48	Rochat B "Role of cytochrome p450 activity in the fate of anticancer agents and in drug resistance : focus on tamoxifen, Paclitaxel and imatinib metabolism." Clin Pharmacokinet 44 (2005): 349-66. [PMID: 15828850]
49	Schroth W, Antoniadou L, Fritz P, et al. "Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes." J Clin Oncol 25 (2007): 5187-93. [PMID: 18024866]
50	Stearns V, Johnson MD, Rae JM, et al. "Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 95 (2003): 1758-64. [PMID: 14652237]
51	Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, Wingren S "Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer." Breast Cancer Res 9 (2007): R7. [PMID: 17244352]
52	Wegman P, Vainikka L, Stal O, et al "Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients." Breast Cancer Res 7 (2005): R284-90. [PMID: 15987423]
53	Young D "Genetics examined in tamoxifen's effectiveness: recurrence warning urged for labeling." Am J Health Syst Pharm 63 (2006): 2286, 2296. [PMID: 17105997]
54	Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM "Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen." Drug Metab Dispos 30 (2002): 869-74. [PMID: 12124303]
55	Ratliff B, Dietze EC, Bean GR, Moore C, Wanko S, Seewaldt VL "Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine." J Natl Cancer Inst 96 (2004): 883 author reply 884-5. [PMID: 15173275]
56	Product Information. Xenazine (tetrabenazine). Prestwick Pharmaceuticals Inc, Washington DC, VA.
57	Carrillo JA, Ramos SI, Herraiz AG, Llerena A, Agundez JAG, Berecz R, Duran M, Benitez J "Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients." J Clin Psychopharmacol 19 (1999): 494-9. [PMID: 10587283]
58	Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82. [PMID: 11691681]
59	Greendyke RM, Gulya A "Effect of pindolol administration on serum levels of thioridazine, haloperidol, phenytoin, and phenobarbital." J Clin Psychiatry 49 (1988): 105-7. [PMID: 3346197]
60	Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
61	Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL.
62	Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
63	Product Information. Evoxac (cevimeline) Daiichi Pharmaceuticals, Fort lee, NJ.
64	Caraco Y, Sheller J, Wood AJJ "Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects." J Pharmacol Exp Ther 290 (1999): 413-22. [PMID: 10381807]
65	Caraco Y, Sheller J, Wood JJ "Pharmacogenetic determination of the effects of codeine and prediction of drug interactions." J Pharmacol Exp Ther 278 (1996): 1165-74. [PMID: 8819499]
66	Desmeules J, Dayer P, Gascon MP, Magistris M "Impact of genetic and environmental factors on codeine analgesia." Clin Pharmacol Ther 45 (1989): 122. [PMID: 1782973]
67	Desmeules J, Gascon MP, Dayer P, Magistris M "Impact of environmental and genetic factors on codeine analgesia." Eur J Clin Pharmacol 41 (1991): 23-6. [PMID: 1782973]
68	Hersh EV, Moore PA "Drug interactions in dentistry: the importance of knowing your CYPs." J Am Dent Assoc 135 (2004): 298-311. [PMID: 15058617]
69	Poulsen L, Brosen K, Srendt-Nielsen L, Gram LF, Elbaek K, Sindrup SH "Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects." Eur J Clin Pharmacol 51 (1996): 289-95. [PMID: 9010701]
70	Sindrup SH, Arendt-Nielsen L, Brosen K, et al "The effect of quinidine on the analgesic effect of codeine." Eur J Clin Pharmacol 42 (1992): 587-92. [PMID: 1623898]
71	Sindrup SH, Brosen K, Bjerring P, et al. "Codeine increases pain threshold to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine." Clin Pharmacol Ther 49 (1991): 686-93. [PMID: 2249379]
72	Sindrup SH, Hofmann U, Asmussen J, Mikus G, Brosen K, Nielsen F, Ingwersen SH, Broen Christensen C "Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake." Eur J Clin Pharmacol 49 (1996): 503-9. [PMID: 8706777]
73	Thorn CF, Klein TE, Altman RB "Codeine and morphine pathway." Pharmacogenet Genomics 19 (2009): 556-8. [PMID: 19512957]
74	Vevelstad M, Pettersen S, Tallaksen C, Brors O "O-demethylation of codeine to morphine inhibited by low-dose levomepromazine." Eur J Clin Pharmacol 65 (2009): 795-801. [PMID: 19308365]
75	Zhou SF "Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II." Clin Pharmacokinet 48 (2009): 761-804. [PMID: 19902987]
76	Product Information. Mektovi (binimetinib). Array BioPharma Inc., Boulder, CO.
77	Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
78	Product Information. Qelbree (viloxazine). Supernus Pharmaceuticals Inc, Rockville, MD.
79	Funck-Brentano C, Jacqz-Aigrain E, Leenhardt A, Roux A, Poirier JM, Jaillon P "Influence of amiodarone on genetically determined drug metabolism in humans." Clin Pharmacol Ther 50 (1991): 259-66. [PMID: 1914360]
80	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
81	Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
82	Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
83	Skinner MH, Kuan HY, Pan A, et al. "Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers." Clin Pharmacol Ther 73 (2003): 170-7. [PMID: 12621382]
84	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
85	Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
86	Okubo M, Murayama N, Miura J, Chiba Y, Yamazaki H "Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients." Biochem Pharmacol 93 (2015): 104-9. [PMID: 25475885]
87	Product Information. Remeron (mirtazapine). Organon, West Orange, NJ.
88	Sitsen JM, Maris FA, Timmer CJ "Concomitant use of mirtazapine and cimetidine: a drug-drug interaction study in healthy male subjects." Eur J Clin Pharmacol 56 (2000): 389-94. [PMID: 11009047]
89	Stormer E, von Moltke LL, Shader RI, Greenblatt DJ "Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4" Drug Metab Dispos 28 (2000): 1168-75. [PMID: 10997935]
90	Product Information. Esbriet (pirfenidone). Intermune Inc, Brisbane, CA.
91	Franco-Salinas G, de la Rosette JJ, Michel MC "Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations." Clin Pharmacokinet 49 (2010): 177-88. [PMID: 20170206]
92	Kamimura H, Oishi S, Matsushima H, et al. "Identification of cytochrome P450 isozymes involved in metabolism of the alpha1-adrenoceptor blocker tamsulosin in human liver microsomes." Xenobiotica 28 (1998): 909-22. [PMID: 9849639]
93	Product Information. Flomax (tamsulosin). Boehringer-Ingelheim, Ridgefield, CT.
94	Edeki TI, He HB, Wood AJJ "Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops: potential for oral-ophthalmic drug interaction." JAMA 274 (1995): 1611-3. [PMID: 7474246]
95	Fraunfelder FT, Fraunfelder FW Randall JA "Drug-Induced Ocular Side Effects 5th" Boston, MA: Butterworth-Heinemann (2001):.
96	Lewis RV, Lennard MS, Jackson PR, Tucker GT, Ramsay LE, Woods HF "Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics." Br J Clin Pharmacol 19 (1985): 329-33. [PMID: 2859048]
97	Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
98	Rojas-Fernandez C, Fisher C "Drug interactions and donepezil." J Am Geriat Soc 40 (2000): 597-8. [PMID: 10811561]
99	Tiseo PJ, Perdomo CA, Friedhoff LT "Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses." Br J Clin Pharmacol 46 (1998): 30-4. [PMID: 9839763]
100	Product Information. Ranexa (ranolazine). Calmoseptine Inc, Huntington Beach, CA.
101	Brynne N, Svanstrom C, AbergWistedt A, Hallen B, Bertilsson L "Fluoxetine inhibits the metabolism of tolterodin-pharmacokinetic implications and proposed clinical relevance." Br J Clin Pharmacol 48 (1999): 553-63. [PMID: 10583026]
102	Product Information. Detrol (tolterodine). Pharmacia and Upjohn, Kalamazoo, MI.

Details of Drug

Details of Drug

Cite MecDDI

About MecDDI

Correspondence